Nalaganje...
Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Shranjeno v:
Main Authors: | , , |
---|---|
Format: | Artigo |
Jezik: | Chinês |
Izdano: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2018-08-01
|
Serija: | Chinese Journal of Lung Cancer |
Teme: | |
Online dostop: | http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
Oznake: |
Označite
Brez oznak, prvi označite!
|